Eli Lilly and Company (LLY)vsTenaya Therapeutics Inc (TNYA)
LLY
Eli Lilly and Company
$1,131.42
-2.41%
HEALTHCARE · Cap: $948.95B
TNYA
Tenaya Therapeutics Inc
$0.73
-5.70%
HEALTHCARE · Cap: $171.43M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 32110567% more annual revenue ($72.25B vs $225,000). LLY leads profitability with a 35.0% profit margin vs 0.0%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
TNYA
Avoid25
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 32.4x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : TNYA
The strongest argument for TNYA centers on Price/Book, Debt/Equity.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book.
Bear Case : TNYA
The primary concerns for TNYA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
LLY profiles as a growth stock while TNYA is a value play — different risk/reward profiles.
TNYA carries more volatility with a beta of 2.77 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 25/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Tenaya Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Tenaya Therapeutics Inc. is a forward-thinking clinical-stage biotechnology firm dedicated to revolutionizing the treatment landscape for heart disease via its proprietary engineered heart cell platform. With a strong pipeline that features cutting-edge gene therapies and regenerative solutions, Tenaya is well-positioned to address critical unmet needs within cardiovascular medicine, presenting compelling growth prospects in the biopharmaceutical industry. The company's focus on scientific excellence and commitment to improving patient outcomes positions it as a noteworthy investment opportunity for institutional investors keen on fostering advancements in cardiac care and capitalizing on the dynamic cardiovascular therapy market.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?